COVID-19 clinical update #124 with Dr. Daniel Griffin
In COVID-19 clinical update #124, Dr. Griffin discusses the results of a variant vaccine booster trial, the neutralization of variant sub-lineages by Novavax, the CDC’s recommendation of Novavax’s COVID-19 vaccine in adults, Paxlovid in patients who are immunocompromised and hospitalized, and inhaled fluticasone for outpatient treatment.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Variant vaccine boosters trial (medRxiv)
- Novavax triggers neutralization of variant sub-lineages (bioRxiv)
- CDC recommends Novavax (CDC)
- Paxlovid in patients who are immunocompromised and hospitalized (The Lancet)
- Inhaled Fluticasone for outpatient treatment (medRxiv)
- PAXLOVID patient eligibility screening checklist (FDA)
- Remdesivir fact sheet for providers (Veklury)
- Bebtelovimab fact sheet for providers (FDA)
- Contribute to FIMRC fundraiser at PWB
- Dr. Griffin’s treatment guide (pdf)
- Letters read on TWiV 921
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
The podcast This Week in Virology is embedded on this page from an open RSS feed. All files, descriptions, artwork and other metadata from the RSS-feed is the property of the podcast owner and not affiliated with or validated by Podplay.